FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2095646977> ?p ?o ?g. }

• W2095646977 endingPage "450" @default.
• W2095646977 startingPage "444" @default.
• W2095646977 abstract "To determine the safety of and immunogenicity induced by A/H1N1 influenza vaccination in patients with systemic lupus erythematosus (SLE). The study population comprised 21 SLE patients and 15 healthy control subjects who underwent split-virion, inactivated monovalent A/H1N1 vaccination between December 2009 and January 2010. Sera were obtained before, three weeks after, and six months after vaccination. SLE disease activity index (SLEDAI) scores and autoantibodies were measured at every visit in SLE patients. Haemagglutination inhibition and the serum immunoglobulin G (IgG) level were calculated using the World Health Organization (WHO) procedure to evaluate the antibody responses. We also recorded current medications and past seasonal influenza vaccinations to analyse the interactions between vaccinations and the autoimmunity of SLE patients. The mean age of the enrolled population was 34.3 years for SLE patients and 39.4 years for control subjects. The average SLEDAI score for SLE patients was 4.1 at vaccination, 4.5 at three weeks, and 4.3 at six months. The seroprotection rate at three weeks was 76.2% in SLE patients and 80.0% in healthy control subjects; by six months, the seroprotection rate was 66.7% in SLE patients and 60% in healthy control subjects. The seroconversion rate was 76.2% in SLE patients and 80% in healthy controls at three weeks; by six months, the seroconversion rate was 52.4% in SLE patients and 53.3% in healthy controls. The response in SLE patients met the criteria of the European Committee for Proprietary Medicinal Products guidelines at three weeks, while the percentage of seroprotection did not at six months. The clinical disease activity and SLEDAI scores did not differ significantly from before to after vaccination in SLE patients, although the level of anticardiolipin IgG increased at three weeks after vaccination, but with no apparent clinical manifestations. The A/H1N1 influenza vaccine is safe and effective in SLE patients and has no obvious adverse clinical effects. Treatment with a single immunosuppressive agent or combination therapy also leads to effective humoral immunity in these patients." @default.
• W2095646977 created "2016-06-24" @default.
• W2095646977 creator A5001330326 @default.
• W2095646977 creator A5009227355 @default.
• W2095646977 creator A5020004898 @default.
• W2095646977 creator A5040370641 @default.
• W2095646977 creator A5068376467 @default.
• W2095646977 creator A5075132888 @default.
• W2095646977 date "2011-01-01" @default.
• W2095646977 modified "2023-10-16" @default.
• W2095646977 title "A/H1N1 influenza vaccination in patients with systemic lupus erythematosus: Safety and immunity" @default.
• W2095646977 cites W1486394209 @default.
• W2095646977 cites W1965434660 @default.
• W2095646977 cites W1971858797 @default.
• W2095646977 cites W1972618758 @default.
• W2095646977 cites W1974559223 @default.
• W2095646977 cites W1983478086 @default.
• W2095646977 cites W1988089513 @default.
• W2095646977 cites W1989948011 @default.
• W2095646977 cites W1996935781 @default.
• W2095646977 cites W1998202733 @default.
• W2095646977 cites W1999205250 @default.
• W2095646977 cites W2016143593 @default.
• W2095646977 cites W2025892793 @default.
• W2095646977 cites W2029074520 @default.
• W2095646977 cites W2041753380 @default.
• W2095646977 cites W2042387310 @default.
• W2095646977 cites W2052118324 @default.
• W2095646977 cites W2052345897 @default.
• W2095646977 cites W2052906913 @default.
• W2095646977 cites W2056808954 @default.
• W2095646977 cites W2060101468 @default.
• W2095646977 cites W2062453938 @default.
• W2095646977 cites W2068127504 @default.
• W2095646977 cites W2071491941 @default.
• W2095646977 cites W2084375134 @default.
• W2095646977 cites W2100779666 @default.
• W2095646977 cites W2112166111 @default.
• W2095646977 cites W2123474370 @default.
• W2095646977 cites W2127132484 @default.
• W2095646977 cites W2141590295 @default.
• W2095646977 cites W2142239745 @default.
• W2095646977 cites W2148958087 @default.
• W2095646977 cites W2149051721 @default.
• W2095646977 cites W2162261696 @default.
• W2095646977 cites W2259526432 @default.
• W2095646977 cites W2312463092 @default.
• W2095646977 cites W4213438764 @default.
• W2095646977 cites W4251323090 @default.
• W2095646977 doi "https://doi.org/10.1016/j.vaccine.2010.10.081" @default.
• W2095646977 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21078406" @default.
• W2095646977 hasPublicationYear "2011" @default.
• W2095646977 type Work @default.
• W2095646977 sameAs 2095646977 @default.
• W2095646977 citedByCount "46" @default.
• W2095646977 countsByYear W20956469772012 @default.
• W2095646977 countsByYear W20956469772013 @default.
• W2095646977 countsByYear W20956469772014 @default.
• W2095646977 countsByYear W20956469772016 @default.
• W2095646977 countsByYear W20956469772017 @default.
• W2095646977 countsByYear W20956469772018 @default.
• W2095646977 countsByYear W20956469772019 @default.
• W2095646977 countsByYear W20956469772021 @default.
• W2095646977 countsByYear W20956469772022 @default.
• W2095646977 countsByYear W20956469772023 @default.
• W2095646977 crossrefType "journal-article" @default.
• W2095646977 hasAuthorship W2095646977A5001330326 @default.
• W2095646977 hasAuthorship W2095646977A5009227355 @default.
• W2095646977 hasAuthorship W2095646977A5020004898 @default.
• W2095646977 hasAuthorship W2095646977A5040370641 @default.
• W2095646977 hasAuthorship W2095646977A5068376467 @default.
• W2095646977 hasAuthorship W2095646977A5075132888 @default.
• W2095646977 hasConcept C126322002 @default.
• W2095646977 hasConcept C159654299 @default.
• W2095646977 hasConcept C203014093 @default.
• W2095646977 hasConcept C22070199 @default.
• W2095646977 hasConcept C2776912625 @default.
• W2095646977 hasConcept C2777451964 @default.
• W2095646977 hasConcept C2779134260 @default.
• W2095646977 hasConcept C2780689484 @default.
• W2095646977 hasConcept C2780868878 @default.
• W2095646977 hasConcept C2908647359 @default.
• W2095646977 hasConcept C71924100 @default.
• W2095646977 hasConcept C99454951 @default.
• W2095646977 hasConceptScore W2095646977C126322002 @default.
• W2095646977 hasConceptScore W2095646977C159654299 @default.
• W2095646977 hasConceptScore W2095646977C203014093 @default.
• W2095646977 hasConceptScore W2095646977C22070199 @default.
• W2095646977 hasConceptScore W2095646977C2776912625 @default.
• W2095646977 hasConceptScore W2095646977C2777451964 @default.
• W2095646977 hasConceptScore W2095646977C2779134260 @default.
• W2095646977 hasConceptScore W2095646977C2780689484 @default.
• W2095646977 hasConceptScore W2095646977C2780868878 @default.
• W2095646977 hasConceptScore W2095646977C2908647359 @default.
• W2095646977 hasConceptScore W2095646977C71924100 @default.
• W2095646977 hasConceptScore W2095646977C99454951 @default.
• W2095646977 hasIssue "3" @default.
• W2095646977 hasLocation W20956469771 @default.

• next